N.C. AG, Endo International Agree to $450M Payment For Nationwide Opioid Settlement

Dow Jones2022-08-18

By Denny Jacob

 

North Carolina Attorney General Josh Stein said an agreement in principle has been reached with Endo International PLC and its lenders for $450 million as part of a nationwide opioid settlement.

The resolution, which will require bankruptcy court approval after the pharmaceutical company filed for chapter 11 protection on Tuesday, will require a $450 million cash payment over a 10-year period to participating states and subdivisions, a permanent marketing ban of Endo's opioids and turning over opioid-related documents for online publication in a public document archive.

"While no amount of money could make whole the people who are grieving their loved ones and people who have lost years of their lives to addiction, these funds will help more people get the help they need to stay alive and stay in recovery," Attorney General Stein said.

The drugmaker, domiciled in Ireland with operations in Malvern, Pa., has faced thousands of lawsuits -- including hundreds from state and local governments -- over the marketing and sale of its painkiller Opana ER, which the company discontinued in 2017 at the request of the U.S. Food and Drug Administration.

Endo had already reached individual settlements with a handful of other state and local governments before it filed for bankruptcy, but still faces about 3,100 lawsuits from state and local governments, private healthcare providers and individuals, according to a court filing by Chief Financial Officer Mark Bradley on Wednesday.

Endo did not immediately respond to a request for comment from Dow Jones Newswires.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

$(END)$ Dow Jones Newswires

August 17, 2022 13:16 ET (17:16 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment